Back to Journals » OncoTargets and Therapy » Volume 10

Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients

Authors Chen J, Li H, Pang RL, Huang J

Received 12 November 2016

Accepted for publication 23 January 2017

Published 6 April 2017 Volume 2017:10 Pages 2003—2007


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Manfred Beleut

Peer reviewer comments 3

Editor who approved publication: Dr Tohru Yamada

Jun Chen, Hui Li, Ronglin Pang, Jia Huang

Department of Chemoradiotherapy, Yinzhou Hospital Affiliated to Ningbo University School of Medicine, Ningbo, People’s Republic of China

Purpose: Programmed death-ligand 1 (PD-L1) is found to be overexpressed in non-small cell lung cancer. The present study intended to evaluate the status of PD-L1 expression in patients with resection and recurrent lung adenocarcinoma.
Patients and methods: Matched resection and recurrent tumor samples were harvested from 65 lung adenocarcinoma patients. Immunohistochemistry was used to evaluate the status of PD-L1 expression. Kaplan–Meier method was used for survival analysis.
Results: A total of 65 patients of lung adenocarcinoma were enrolled. They underwent complete resection and had recurrence after adjuvant treatment. PD-L1 expression was identified in 43.1% (28/65) of resection samples vs 55.4% (36/65) of recurrent samples. Ten patients shifted from negative to positive, whereas another two samples showed the opposite. Patients with PD-L1 expression showed worse disease-free survival than the PD-L1-negative counterparts. The expression of PD-L1 in recurrent samples was a significant favorable factor for epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) (11.2 vs 8.2 months, P=0.030).
Conclusion: The status of PD-L1 expression may alter between resection and recurrent samples. Also, the status of PD-L1 expression after recurrence is a better prognostic factor for EGFR-TKIs.

programmed death-ligand 1, overexpression, lung adenocarcinoma, survival

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]